DMAC
DiaMedica Therapeutics Inc
7.60$
-2.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.5% | 93.6% | 99.0% | 82.9% | 98.0% | 97.6% | 99.4% | 99.8% | 98.4% | 99.1% | 96.3% | 98.8% | |
| 72.4% | 74.5% | 92.7% | 75.1% | 91.7% | 42.9% | 26.4% | 10.3% | 13.7% | 8.4% | 6.5% | 25.5% | |
| 72.4% | 74.5% | 92.7% | 75.1% | 91.7% | 87.0% | 97.9% | 99.0% | 97.4% | 97.7% | 95.3% | 97.6% | |
| 3.0% | 4.3% | 2.8% | 4.4% | 3.5% | 9.1% | 1.2% | 0.3% | 0.2% | 0.7% | 0.5% | 0.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.2% | – | – | – | – | |
| 5.5% | 6.4% | 1.0% | 2.1% | 0.5% | 2.4% | 0.3% | 0.2% | 1.6% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 643.0% | 652.8% | 33.5% | 55.7% | 7.2% | 15.9% | 7.4% | 3.4% | 7.5% | 5.7% | 12.1% | 8.6% | |
| 643.0% | 478.3% | 33.5% | 55.7% | 7.1% | 14.6% | 7.2% | 3.3% | 6.3% | 5.1% | 11.6% | 8.4% | |
| 0.0% | 117.5% | 10.7% | 0.0% | 0.0% | 0.7% | 0.2% | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | |
| 340.9% | 303.1% | 13.3% | 28.5% | 2.6% | 2.0% | 3.9% | 1.1% | 2.1% | 1.7% | 2.0% | 2.4% | |
| 0.0% | 175.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| -543.0% | -552.8% | 66.5% | 44.3% | 92.8% | 84.1% | 92.6% | 96.6% | 92.5% | 94.3% | 87.9% | 91.4% | |
| -13,801.9% | -15,266.7% | -2,493.8% | -2,232.7% | -250.7% | -625.4% | -245.3% | -181.1% | -279.6% | -213.4% | -302.1% | -281.5% | |
| 1,103.4% | 1,629.8% | 252.8% | 329.4% | 42.2% | 132.4% | 55.8% | 45.6% | 76.9% | 60.1% | 87.2% | 76.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.